Join the SOSV DEEP TECH SUMMIT, NOV 4-6. (FREE AND VIRTUAL ) Register Today →

Cell BioEngines

Off-the-shelf, HLA-matched cell therapies without genetic engineering

Company details

Cell BioEngines develops allogeneic, off-the-shelf cell therapies for oncology applications. Its transgene-free platform chemically reprograms HLA-homozygous cord blood stem cells into HAPLO immune and iPSC products for scalable, low-cost manufacturing. HLA-guided biobanking and population-informed donor selection enable broad patient coverage while aiming to reduce immune rejection.

Cell-based immunotherapy in cancer has shown a game-changing improvement demonstrating 60% of patients in complete remission after 5 years of treatment.

Cell BioEngines Quote Image
Ajay Vishwakarma, Founder & CEO
“In the future, next-generation cell therapies for cancer will be available ‘off-the-shelf’ as ‘drugs’ with discrete controlled phenotype or state driving consistent anticancer functions.”

Team

Ajay Vishwakarma

Founder and CEO

Alexey Bersenev

CTO

Get In Touch with Cell BioEngines

Please tell us a little bit about yourself and why you'd like to get connected. Cell BioEngines + SOSV will follow up with you via email.

This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form

No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.